ReviewFrontiers in genetics2020
Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities.
Review in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- ONT-only genome assembly of a Korean male individual using a semen sample.Genes & genomics · 2026Article
- Article
- Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection.OncoTargets and therapy · 2025Article
- Review
- Comparative Analyses of Targeted Myeloid Cancer Next-Generation Sequencing Panel in Fresh Blood, Bone Marrow and FFPE Material.International journal of molecular sciences · 2024Article
- The whole is greater than the sum of its parts: Long-read sequencing for solving clinical problems in haematology.Journal of cellular and molecular medicine · 2024Article
- The potential of 3rd-generation nanopore sequencing for B-cell clonotyping in lymphoproliferative disorders.EJHaem · 2024Article
- Genewise detection of variants inFrontiers in genetics · 2024Article
- Nanopore Single-molecule Analysis of Biomarkers: Providing Possible Clues to Disease Diagnosis.Trends in analytical chemistry : TRAC · 2023Article
- Case report: biallelicFrontiers in oncology · 2023Article
- Biohybrid Membrane Formation by Directed Insertion of Aquaporin into a Solid-State Nanopore.ACS applied materials & interfaces · 2022Article
- Evaluation of the Available Variant Calling Tools for Oxford Nanopore Sequencing in Breast Cancer.Genes · 2022Article
- Recent advances in aptamer applications for analytical biochemistry.Analytical biochemistry · 2022Article
- Article
- Accuracy of an amplicon-sequencing nanopore approach to identify variants in tuberculosis drug-resistance-associated genes.Microbial genomics · 2021Article
- Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia.Scientific reports · 2021Article
- High-QualityFrontiers in genetics · 2021Article
- STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studies.The Lancet. Infectious diseases · 2020Review
- Epitranscriptomics in Normal and Malignant Hematopoiesis.International journal of molecular sciences · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular pathogenesis of hematological diseases is often driven by genetic and epigenetic alterations. Next-generation sequencing has considerably increased our genomic knowledge of these disorders becoming ever more widespread in clinical practice. In 2012 Oxford Nanopore Technologies (ONT) released the MinION, the first long-read nanopore-based sequencer, overcoming the main limits of short-reads sequences generation. In the last years, several nanopore sequencing approaches have been performed in various "-omic" sciences; this review focuses on the challenge to introduce ONT devices in the hematological field, showing advantages, disadvantages and future perspectives of this technology in the precision medicine era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.